Acurex Biosciences moves 15-lipoxygenase program closer to Parkinson’s disease clinical testing
Parkinson’s drugs still treat symptoms. Acurex’s ASAP grant puts 15-lipoxygenase and ferroptosis into sharper disease-modifying focus.
Why everyone watching neurology at AAN 2026 may end up talking about Acadia Pharmaceuticals
Acadia Pharmaceuticals heads to AAN 2026 with Daybue, Nuplazid, and ACP-711 data. Read what the updates could mean for its neurology strategy.
Could Praxis Precision Medicines’ Phase 3 ulixacaltamide data redefine the treatment pathway in essential tremor?
Praxis Precision Medicines’ positive Phase 3 ulixacaltamide data could reshape essential tremor treatment. Discover what this means for neurology and investors.
Insightec’s focused ultrasound therapy secures French reimbursement. Could incisionless brain procedures expand across Europe?
France approves reimbursement for MR-guided focused ultrasound in essential tremor. Discover what the policy change means for neurosurgery and patient access.